HTR2A Genotype

If you've cycled through two or three antidepressants without much to show for it, you've probably wondered whether something about your biology is working against you. This result looks at one small piece of that puzzle: the gene that builds a serotonin docking point on brain cells.

Set expectations correctly. This is a research-grade pharmacogenetic marker, not a stand-alone prescribing tool. CPIC reviewed the evidence and found dosing guidance for CYP2D6, CYP2C19, and CYP2B6, but not for HTR2A. No guideline tells a prescriber to change your medication based on this result alone.

What This Test Actually Reads

HTR2A sits on chromosome 13. It carries the instructions for building the serotonin 2A receptor, a protein on the surface of brain cells that serotonin latches onto. Some psychiatric drugs act directly on this receptor, and SSRI response studies keep finding small associations with variants in the gene.

Most pharmacogenetic panels use blood, saliva, or cheek-swab cells only to collect your DNA. The genotype should be the same from any of those samples, because this is a germline result. You inherited one copy from each biological parent, and that pairing is fixed for life.

The five spots that show up most in the research are rs6311 near the gene's on-switch region, rs6313 and rs6314 in coding stretches, rs7997012 inside the gene, and rs3125 in a regulatory stretch. Different labs read different combinations, so two reports on the same person can list different variants without either being wrong.

Antidepressant Response and Side Effects

The clearest clinical signal is about side effects, not choosing the best drug. SSRIs are a common class of antidepressant. A pooled analysis found that people with two G copies at rs6311, using the common -1438G/A naming, had almost twice the odds of side effects during SSRI treatment compared with other genotypes.

That does not make the result a green or red light for any one drug. It may matter when you and your prescriber are trying to explain a pattern of early side effects that keeps repeating.

On whether the drug works at all, the evidence is softer. A STAR*D analysis of 1,953 people treated with citalopram linked rs7997012 to treatment outcome. A later gene-level study found HTR2A variants associated with SSRI response in 455 treated people, while the same gene did not clearly separate people with depression from controls. That distinction matters: this is mainly a response marker, not a disease-risk marker.

If you've had a pattern of quitting antidepressants early because of side effects rather than lack of benefit, a G/G result at rs6311 is one more piece of evidence that the pattern may be partly biological. It is a reason to discuss starting at a lower dose and raising it more slowly, or trying a different class, with whoever prescribes for you. It is not a reason to avoid antidepressants.

Treatment Resistance

Two retrospective studies looked at rs7997012 in people already dealing with treatment-resistant psychiatric illness. In 210 people with treatment-resistant conditions, A/A at rs7997012 was much more common in those whose resistant illness was obsessive-compulsive disorder than in those with other resistant disorders. The best estimate was nearly sevenfold higher odds, but the uncertainty was wide, roughly twofold to nineteenfold.

In a separate 129-person study, the A/G pairing predicted high resistance to second-generation antipsychotics, about sevenfold compared with A/A and about threefold compared with G/G. This was a small real-world sample, not a trial that followed newly treated people from the start.

Read those findings narrowly. They compare difficult-to-treat groups against other difficult-to-treat groups. They do not tell you your odds of becoming treatment-resistant if you are doing fine on your current medication.

Antipsychotic Response

For rs6313, the pooled antipsychotic evidence is mixed. Across all studies, the variant did not predict response in a clean way. In subgroup analyses, people of European ancestry with the T version tended to respond better, while East Asian groups and clozapine-treated groups showed a better response pattern for the T/C pairing.

An effect that changes by ancestry or drug is a warning sign. It may reflect real differences in nearby DNA that travels with each variant in different populations, or it may reflect small studies finding different things. Either way, a result interpreted without ancestry and medication context is weak evidence.

Pain Sensitivity

Serotonin 2A receptors also matter in pain pathways. In a study with 240 people with nerve pain and 253 healthy controls, rs6313 variant carriers in one sensory-pattern subgroup reported about 30% higher ongoing pain and showed more signs of an over-amplified pain system. That state is called central sensitization.

A smaller study of 117 people with jaw muscle pain found that a different HTR2A variant was linked to higher pain intensity. That supports a broader serotonin-receptor pain link, not the exact same variant measured in every psychiatric panel.

This is the association most people testing for psychiatric reasons don't expect. If you carry a pain-linked variant and have unexplained chronic pain alongside mood symptoms, the two may share a pathway rather than one simply causing the other.

Why the Same Gene Shows Up in So Many Places

Look at the list and it can seem suspicious: drug response, OCD, pain, suicide risk under stress. A gene linked to everything can turn out to be linked to nothing in particular.

There is a better explanation. This receptor is part of circuits that handle mood, impulse control, and pain signaling at the same time, so nudging it slightly may nudge several things slightly. That fits the size of the effects: small, inconsistent across populations, and heavily dependent on what else is happening in someone's life.

A study of 1,568 people with depression found that rs3125 raised suicide-attempt risk only in combination with negative life events. Another 138-person mood-disorder study found that rs6313 predicted whether someone's illness ran toward depression or toward mania only when inflammation was low, measured with platelet-derived inflammation markers. That is why hs-CRP can give rough context, but it is not the same marker used in that study.

What a Result Doesn't Tell You

A genotype tells you which version of the instructions you carry, not how many receptors your brain actually built. PET brain imaging in 197 healthy adults found that common HTR2A variants did not predict actual serotonin 2A receptor levels. So a report labeled increased sensitivity is describing a statistical association in study populations, not a measurement of anything in your head.

Five limits are worth holding onto:

• Panel coverage: the test reads only the variants it was designed to read. A result showing nothing unusual does not rule out other rare changes elsewhere in the gene.
• Ancestry: how common each version is, and what it predicts, differs across populations. A report that ignores your background may overread the result.
• Uncertain findings: sequencing can turn up a rare change nobody has characterized yet. That means the variant simply has not been studied enough to interpret, not that you have a condition.
• Clinical-grade testing: raw direct-to-consumer data can have strand, quality, and interpretation problems. Use a clinical-grade result for medical decisions.
• Sample problems: your inherited result should reflect the DNA you were born with. A transplant, blood cancer, sample mix-up, or contamination can make a DNA result less straightforward.

There is also a general sequencing point. Across a review of 450,000 clinical sequencing results, about one in seven disease-causing changes were the kind that standard sequencing pipelines can struggle with, such as small insertions, deletions, or duplicated stretches. That is a general limit of sequencing, not a finding about HTR2A. For the single-letter changes this test usually focuses on, the problem is smaller, but an unexpected result can still warrant confirmation by another method.

A One-Time Result You Use for Years

Your genotype won't change. Test it once and there is no trend line to follow. What changes is how useful the result becomes as the evidence base improves and as you build your own history of what worked and what did not.

That history is the thing worth tracking. Keep a written record of every psychiatric medication you've tried: the dose, how long you stayed on it, what improved, what side effects showed up, and when you quit. Paired with your genotype, that record is more useful to a prescriber than either piece alone. Repeat the genotype only if the lab flags low confidence, the sample may have been mixed up, or a new report contradicts an old one.

What to Do With an Unexpected Result

If you are choosing tests, a broader pharmacogenomic panel that includes CYP2D6, CYP2C19, and CYP2B6 has more direct prescribing value for several serotonin reuptake inhibitors. HTR2A adds context. Those genes can change dose or drug choice for specific medications.

If a direct-to-consumer file and a clinical report disagree, use the clinical-grade result or confirm by a second method before acting on it. If the result is part of a broader panel that reports unexpected disease-risk variants, a genetic counselor can help sort out what applies to you and what does not.

Beyond that, the pathway depends on what the result sits next to. A side-effect-prone genotype alongside a history of quitting antidepressants in the first month is a conversation about a slower dose increase or a different class of drug. A result suggesting treatment resistance alongside multiple failed adequate trials is a reason to ask a psychiatrist about adding a second medication or switching to one that works through a different mechanism. A pain-linked variant alongside unexplained chronic pain is worth raising with a pain specialist, because standardized sensory testing can show whether your nervous system is amplifying signals.

If the result shows nothing notable, that changes nothing about your treatment. Standard clinical assessment, your own medication history, and drug-level monitoring for medications where it applies remain better guides than any single receptor variant.